Please login to the form below
Thyroid eye disease
This page shows the latest Thyroid eye disease news and features for those working in and with pharma, biotech and healthcare.
FDA approves Horizon's thyroid eye disease drug ahead of schedule
First FDA-approved treatment for rare autoimmune condition. Horizon Therapeutics has won a speedy approval for its thyroid eye disease (TED) treatment Tepezza in the US. . ... We believe teprotumumab may impact underlying mechanisms of fibrosis and
Latest news
-
Horizon looks bright as FDA panel backs eye drug teprotumumab
thyroid eye disease (TED). ... It’s most often caused by an overactive thyroid gland (Graves’ disease), and occurs in around one in four people with that condition.
-
Horizon sunny as thyroid eye disease drug hits the mark
New treatment helps lessen eye bulging. Horizon Pharma shares rose strongly after it reported a positive phase 3 trial of teprotumumab for the treatment of active thyroid eye disease (TED), which ... If approved, teprotumumab would give physicians the
-
FDA awards $19m in rare disease grants
One study – to investigate neonatal respiratory distress syndrome – received $1.4m; one involving thyroid eye disease received $1.2m; and three more received less than $1m.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
43% complete responses indicating the disease had disappeared entirely. ... Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
Spirit
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
